Prophylaxis and treatment of Pneumocystis carinii pneumonia.
Although Pneumocystis carinii pneumonia (PCP) can occur in any patient with severe impairment of immunity, there has been a sharp rise in incidence with the spread of human immunodeficiency virus through the USA and Western Europe, where nearly 80% of patients with HIV infection have at least one episode of PCP during their lifetime (Murray et al, 1984).
O'Doherty
M J
MJ
Department of Nuclear Medicine, St Thomas' Hospital, London.
Bateman
N T
NT
D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000737:chemistry; D002985:Clinical Protocols; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations; D015658:HIV Infections / Q000097:blood / Q000150:complications*; D015497:HIV-1; D006801:Humans; D010419:Pentamidine / Q000008:administration & dosage / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use; D013413:Sulfadoxine / Q000008:administration & dosage / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage / Q000627:therapeutic use*
D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D013413:Sulfadoxine; D003622:Dapsone; D011739:Pyrimethamine